BrainsGate Ltd., a Caecarea, Israel-based developer of an electrical stimulation system that helps certain CNS disorders, has raised $27.5 million in Series C funding. Johnson & Johnson Development Corp. led the round, and was joined by VC-Fund Agate Medical Investments and return backers Elron Electronic Industries, Pitango Venture Capital, MB Venture Capital and Alice Lab.
BrainsGate Ltd., a developer of an innovative therapeutic platform technology based on electrical neurostimulation of the Spheno-Palatine Ganglion, today announced the completion of a $27.5M series C financing round in which both new and existing investors participated.
Johnson & Johnson Development Corporation (JJDC) led the round, joined by VC-Fund Agate Medical Investments LP, headed by
“This investment, paired with the substantial experience of our new and existing investors, will serve as key driving factors in enabling the company to move ahead in conducting the pivotal clinical study. This study represents a key stage in the Company's progress in gaining market approval for its innovative acute ischemic stroke treatment,” commented Avinoam Dayan, CEO of BrainsGate, adding “I would like to welcome our new investors, while thanking our existing shareholders for their ongoing support of the Company.”
BrainsGate is a developer of a novel therapeutic platform based on electrical neurostimulation of the Spheno-Palatine Ganglion (SPG). BriansGate's leading indication is acute ischemic stroke with a 24 hour treatment window. The company is nearing completion of a multi-national multi-center pilot clinical study which to date has recruited over 90 stroke patients, and is about to initiate a pivotal study to gain market approval for its stroke therapy.
For more information please visit www.brainsgate.com.